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A Cautionary Case: The Synergraft Vascular Prosthesis
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To date no prosthetic vascular prosthesis performs as well as autologous conduits for small diameter arterial reconstruction.
We report the outcome of our first case using a new vascular prosthesis marketed by Cryolife, the SynerGraft. This Xenograft
prostheses is claimed to eliminate the problems of the previous generation of gluteraldehyde treated grafts. Two 50 cm
SynnerGrafts were anastomosed end to end and used as a femoral-posterior tibial bypass graft in a 68-year-old man who
presented with an acutely ischaemic left leg. Our patient represented at 8 weeks with aneurysmal degeneration along the
course of the graft. We urge caution in the use of these grafts until convincing data in humans is presented.
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Introduction
To date no prosthetic vascular prosthesis performs as
well as autologous conduits for small diameter arterial
reconstruction.1,2 We report the outcome of our first
case using a new vascular Xeno prosthesis marketed
by Cryolife, the SynerGraft.3 The SynerGraft is a new
product produced by Cryolife. It is produced from
Bovine ureter and comes as a 7 mm diameter conduit
in lengths of between 30 and 75 cm stored in a buffer
solution at room temperature for utilisation off the
shelf. The manufacturing process is different from
previously marketed Xenograft prostheses.4,5 The
novel patented process involves denuding bovine
ureters of cells by a sequence of hypotonic lysis and
digestion with nucleases to leave just the underlying
collagen matrix, thus epithelial cells, smooth muscle
and fibroblasts are completely removed. When
implanted in an animal dog model the grafts have
been reported to be repopulated by host cells consist-
ing of capillary in-growth, circumferentially oriented
smooth muscle cells in the media and a luminal layer
of cells resembling endothelium.3 The viability of the
repopulated graft is claimed to eliminate the problems
of the previous generation of gluteraldehyde treated
grafts, known to be aneurysm formation, calcification
of the conduit, neointimal hyperplasia, stenosis and
occlusion.4,6 – 8
Report
A 68-year-old man presented with an acutely ischae-
mic left leg. He had previously undergone extensive
vascular surgery for aneurysmal disease, including an
Aortic graft and a femoral-posterior tibial bypass graft.
A duplex scan demonstrated that the femoral-pos-
terior tibial graft in the left leg had occluded but the
posterior tibial artery remained patent into the foot.
There was no long saphenous vein available because
both veins had been harvested for previous surgery.
Arm vein was considered but was not utilisable due to
recent repeated venepuncture. The foot had reduced
sensation with no Doppler signals and urgent inter-
vention was required. Thrombolysis was unlikely to
achieve revascularisation soon enough. It was decided
that revascularisation to the posterior tibial artery with
a synthetic graft was the only option. Two 50 cm
SynnerGrafts were anastomosed end-to-end and used
as a femoral-posterior tibial bypass graft, achieving
revascularisation of the foot with return of the
posterior tibial pulse.
Our patient represented at 8 weeks with erythema-
tous swellings along the course of the graft increasing
in size since he first noticed the change 3 weeks prior
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to representation. Otherwise, he was asymptomatic
without pain, fever, malaise or change in his walking
distance. On examination, the swellings were pulsatile
and expansile measuring up to 2.6 cm in diameter.
(Fig. 1) Vitals signs and blood tests were unremarkable
and blood cultures showed no growth. It was decided
to remove the SynerGraft due to the impending risk of
rupture. (Fig. 2). There was difficulty removing the
graft completely as some segments were densely
adherent especially around the distal cuff and some
sections of the graft were friable. Segments of the graft
were sent for histology and microbiological culture.
The graft tunnel was washed out with dilute aqueous
iodine solution. Cephalic vein from both arms was
harvested and joined end to end to achieve sufficient
length to replace the SynerGraft and routed in the
existing tunnel. He made an uneventful recovery from
the surgery. He entered graft surveillance and this
remained satisfactory at 6 months. The microbiology
specimen demonstrated occasional pus cells on Gram
smear but no organisms and subsequent culture was
negative. Histology of the graft demonstrated the wall
to consist of highly vascularised fibromuscular tissue,
containing a dense transmural inflammatory cell
infiltrate. This comprised numerous eosinophils,
with scattered granulomata including multinucleated
giant cells. The luminal surface was lined by thrombus
that contained large numbers of neutrophils in areas
(Fig. 3).
Discussion
The utilisation of bovine ureter as the source material
for a vascular conduit is not new. Gluteraldehyde
treated bovine ureter for use as vascular prosthesis has
been reported since 1982.9 The manufacturer claims
that the modification in production of its SynerGraft
renders it unlikely to undergo aneurysmal degener-
ation and it has been used for dialysis a-v fistulae
without apparent problems, but our experience
demonstrates aneurysmal degeneration is possible.
The histological examination of the explanted
SynerGraft did not suggest hyper-acute immune
response to the Xenograft but simply an inflammatory
response. An inflammatory response is expected and
is promoted by the manufacturer as part of a
revitalisation process and was still ongoing at 13
weeks in their dog experiment.3 Considering that prior
to implantation bench testing has shown the grafts
have similar burst strength to long saphenous vein,10
we hypothesise that it is the inflammatory response
that is responsible for weakening of the wall. The
absence of aneurysm formation in the six reported
cases in the dog animal model studied beyond 6
weeks, taken at face value, may suggest the inflam-
matory response is different in humans or just that
insufficient numbers have been studied.3
The company has suggested a future area of
development for their graft, is to repopulate the graft
in vitro prior to implantation. It may be that if this were
accomplished successfully, it would ameliorate the
inflammatory response on implantation which we are
led to conclude was responsible for the failure of the
graft wall integrity.
We urge caution in the use of these grafts until
convincing data in humans is presented.
Fig. 1. Swellings along the course of the graft prior to
explantation.
Fig. 2. Explanted graft, showing areas of aneurysmal degeneration.
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Fig. 3. Histology of the explanted graft: (a) inflammation throughout the wall, (b) numerous eosinophils, (c) granulomata and
(d) the luminal surface lined by inflamed thrombus.
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